(Press-News.org) Doctors have found that metformin, an everyday medicine for diabetes, is associated with less progression of age-related macular degeneration (AMD), the commonest cause of blindness in western countries.
People with diabetes over the age of 55 years taking metformin were 37% less likely to develop the intermediate stage of AMD over a five year period compared to those not taking metformin.
AMD is a disease which affects the central retina or macular at the back of the eye. It eventually causes the light-sensitive tissue to die off (geographic atrophy, a form of ‘dry’ AMD) or be damaged by abnormal blood vessel growth (‘wet’ AMD). Intermediate and advanced AMD affects 10-15% of people over 65 years of age (1.1 to 1.8 million people in the UK), and is the commonest cause of blindness in high-income countries.
The annual cost of AMD is estimated to be £11.1billion in the UK. Geographic atrophy has no treatment in the UK and Europe, while treatments for wet AMD are expensive and unpleasant (repeated injections into the eye).
The research from the University of Liverpool used pictures taken of the eyes of 2,000 people attending the routine diabetic eye disease screening programme in Liverpool over 5 years. The researchers assessed whether AMD was present on the photographs and how severe it was, and then compared those taking metformin and those who were not. They also adjusted for factors which might bias the result such as age, sex, and duration of diabetes. The odds of developing intermediate AMD over 5 years in the metformin group was 0.63 compared to the no metformin group (95% confidence range 0.43 to 0.92).
A potential benefit from metformin in AMD has been suspected before, but this is the first study to grade AMD from eye photographs. Previous studies on metformin have used secondary information on AMD such as GP diagnostic codes, or insurance claims in the US.
Dr Nick Beare, an eye doctor who led this research, says: “Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments. What we need to do now is test metformin as a treatment for AMD in a clinical trial. Metformin has the potential to save many people’s sight.”
The research paper will be published in the BMJ Open Ophthalmology on 03 Feb 2026, 04:00 UK time: http://dx.doi.org/10.1136/bmjophth-2025-002339
Notes to editors
Metformin
Metformin taken as a tablet, is the first line treatment for type 2 or adult-onset diabetes. It reduces the production of sugar (glucose) in the liver along with other effects which benefit diabetes. Metformin also has anti-aging effects including being antioxidant, anti-inflammatory and stimulating house-keeping functions and energy production in cells (pro-mitochondria). Metformin is an off-patent medicine and is cheap (about £50/patient/year in the NHS). Side-effects include initial nausea and diarrhoea, and rarely kidney damage in people who are dehydrated.
AMD in Society
Dame Judi Dench, Sir John Mills, Stephen King, Roseanne Barr and June Brown (Dot Cotton) have all publicly acknowledged sight loss due to AMD. Edgar Degas, the impressionist painter, is thought to have suffered from AMD which affected his style of painting in later years.
END
Everyday diabetes medicine could treat common cause of blindness
2026-02-03
ELSE PRESS RELEASES FROM THIS DATE:
Ultra-thin metasurface chip turns invisible infrared light into steerable visible beams
2026-02-03
New York, February 2, 2026 — The invention of tiny devices capable of precisely controlling the direction and behavior of light is essential to the development of advance technologies. Researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have taken a significant step forward with the developed of a metasurface that can turn invisible infrared light into visible light and aim it in different directions—without any moving parts. The details of their work are explained in a new paper published in the journal eLight.
The novel metasurface is constructed of an ultra-thin chip patterned with ...
Cluster radioactivity in extreme laser fields: A theoretical exploration
2026-02-03
From Laser Breakthroughs to New Frontiers in Nuclear Decay Control
With the continuous progress in experimental laser technology, significant improvements in laser energy and peak intensity have been achieved in recent years. The direct interaction between intense lasers and atomic nuclei has emerged as an exciting new possibility, one capable of altering nuclear decay lifetimes. Investigating the influence of strong laser fields on nuclear decay can elucidate how these fields affect nuclear structure ...
Study finds banning energy disconnections shouldn’t destabilise markets
2026-02-03
Approaches by some European countries and Australia to protect energy consumers could help countries worldwide phase out harmful electricity disconnections without destabilising power markets, new research has found.
The RMIT University-led study examines protections in Spain, France and Ireland and outlines how similar measures could be adapted in other competitive energy markets to reduce the harms caused by disconnections for non‑payment.
Across Europe, 20 million households were disconnected from electricity and gas at some point during 2022, according to the EU Agency for the Cooperation ...
Researchers identify novel RNA linked to cancer patient survival
2026-02-02
In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus (a dense region of the cell containing a subset of crucial genetic material). Their findings also suggest this molecule may influence patient survival in certain blood cancers.
A surprising discovery inside a familiar gene
RNA, or ribonucleic acid, is a short-lived molecule copied from DNA that enables cells to use genetic information. Specific DNA ...
Poverty intervention program in Bangladesh may reinforce gender gaps, study shows
2026-02-02
URBANA, Ill. – In Bangladesh, programs targeting ultra-poor, rural households can help families escape extreme poverty. However, the programs may have the unintended consequence of reinforcing gender gaps, a new study from the University of Illinois Urbana-Champaign finds.
“We were interested in looking at whether such interventions influence parents’ expectations for their children’s education and occupation, which can promote social mobility. Because there are huge disparities between boys and girls in Bangladesh, we also wanted to see if it affected the gender gap,” said lead author Alejandro Montoya Castaño. He was a doctoral ...
Novel approach to a key biofuel production step captures an elusive energy source
2026-02-02
Plants grown for biofuel have the potential to power our travel industry, but an important fraction of their chemical power has remained stubbornly difficult to recover. New research from the DOE-funded Center for Advanced Biofuel and Bioproduct Innovation on the University of Illinois campus has demonstrated a way to preserve native lignin structure, a key component of plant matter for conversion to other valuable products, putting an improved pathway for biofuel and bioproduct production within reach.
The ...
‘Ghost’ providers hinder access to health care for Medicaid patients
2026-02-02
Almost one-third of physicians who are enrolled in Medicaid don’t actually care for a single patient covered by Medicaid insurance, according to new research led by Oregon Health & Science University.
The study, published today in the journal Health Affairs, sheds new light on a program that covers nearly 80 million Americans.
Researchers also found that another third of health care providers enrolled in Medicaid see a high volume of patients — more than 150 annually — and may be overburdened. Combined, the findings paint a picture of a situation in which enrollment data alone may obscure the reality ...
Study suggests far fewer cervical cancer screenings are needed for HPV‑vaccinated women
2026-02-02
Embargoed for release until 5:00 p.m. ET on Monday 2 February 2026
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on ...
NUS CDE researchers develop new AI approach that keeps long-term climate simulations stable and accurate
2026-02-02
Hybrid climate modelling has emerged as an effective way to reduce the computational costs associated with cloud-resolving models while retaining their accuracy. The approach retains physics-based models to simulate large-scale atmospheric dynamics, while harnessing deep learning to emulate cloud and convection processes that are too small to be resolved directly. In practice, however, many hybrid AI-physics models are unreliable. When simulations extend over months or years, small errors can accumulate and cause the model to become unstable.
In a new ...
UM School of Medicine launches clinical trial of investigative nasal spray medicine to prevent illnesses from respiratory viruses
2026-02-02
Last year, at least one million people in the U.S. were hospitalized for respiratory virus illnesses like the flu or COVID-19, according to the Centers for Disease Control and Prevention. Many of these individuals were at higher risk of getting infections due to living or working around young children who contract more respiratory infections. A new clinical trial led by researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD) will test a new experimental intranasal ...